)

Idorsia (IDIA) investor relations material
Idorsia Status Update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Innovation and Mechanism of Action
TRYVIO (aprocitentan) is the first FDA-approved dual endothelin receptor antagonist for systemic hypertension, offering a novel mechanism for patients with difficult-to-control hypertension after decades of limited progress.
It targets both ETA and ETB receptors, providing efficacy in upregulated endothelin systems and a strong safety and tolerability profile.
The endothelin pathway is particularly relevant for high-risk groups, including Black patients, elderly, postmenopausal women, obese individuals, and those with CKD, diabetes, heart failure, or sleep apnea.
TRYVIO is included in updated ACC/AHA guidelines and is nominated for the 2025 Prix Galien USA Awards.
Clinical Evidence and Patient Populations
Clinical trials demonstrated rapid, significant, and sustained blood pressure reductions, including in high-risk and resistant hypertension subgroups, with effects seen as early as two weeks and maintained up to 48 weeks.
TRYVIO showed unique efficacy in reducing nighttime blood pressure and urine albumin-to-creatinine ratio, with stable eGFR in CKD stage 3/4 patients.
Blood pressure-lowering effects were consistent across age, sex, race, BMI, kidney function, and diabetes status.
The FDA-approved label covers a broader population than the trial, including adults inadequately controlled on other antihypertensives and highlights cardiovascular risk reduction.
TRYVIO demonstrated good tolerability, minimal side effects, no drug-drug interactions, and no signals for hyperkalemia or hypotension, supporting its use in patients on multiple therapies.
Market Opportunity and Commercial Strategy
Nearly 26 million US patients are inadequately controlled on other drugs and eligible for TRYVIO, with 30–50% of treated patients falling into this category.
An initial focus is on 7 million easily identifiable patients, especially those with CKD, who have limited options and for whom TRYVIO is approved down to EGFR 15.
Over 1,000 physician interactions confirm strong recognition of TRYVIO's efficacy, safety, and unique mechanism, with favorable payer responses and a WACC set at $775/month.
Geographic expansion opportunities exist in the EU, UK, Japan, China, and further value is possible through IP extension, fixed-dose combinations, and new indications.
TRYVIO is approved and commercially available in the US since October 2024, also approved as JERAYGO in the EU and UK, with applications under review in Canada and Switzerland.
Next Idorsia earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage